Louisiana HCR120 establishes the PACE Task Force to study GLP-1 medications' clinical history, accessibility, and insurance costs.
Louisiana HCR120 creates the PACE Task Force to study GLP-1 medications, focusing on their clinical history, accessibility, and impact on insurance costs. The task force will examine pricing differences for diabetes versus weight loss, the effect on insurance premiums, and whether higher-risk enrollees are attracted to plans covering GLP-1 medications. The task force will also consider whether employers restrict coverage to control premium growth and if lower-income or uninsured populations face disproportionate exclusions due to costs.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.